Summit Therapeutics
SMMT
232 hedge funds and large institutions have $2.12B invested in Summit Therapeutics in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 80 increasing their positions, 70 reducing their positions, and 45 closing their positions.
26% more call options, than puts
Call options by funds: $115M | Put options by funds: $91.1M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 70
2% more capital invested
Capital invested by funds: $2.08B → $2.12B (+$44.3M)
0.67% more ownership
Funds ownership: 13.18% → 13.85% (+0.67%)
7% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 45
3% less funds holding
Funds holding: 238 → 232 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$56.8M |
| 3 |
Morgan Stanley
New York
|
+$31.2M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$24.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.8M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$13.6M |
| 3 |
Millennium Management
New York
|
-$10.6M |
| 4 |
Charles Schwab
San Francisco,
California
|
-$10.1M |
| 5 |
RT
Rockland Trust
Hanover,
Massachusetts
|
-$8.51M |
SMMT Hedge Fund Activity: Q3 2025 in Review
232 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2025, worth a combined $2.12B — up 2.1% from $2.08B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of SMMT and 42 opened new positions — a net loss of 3 holders — while 70 trimmed existing stakes and 80 added.
The largest buyer was Vanguard Group, adding an estimated $65.6M. The largest seller was UBS Group, cutting an estimated $19.8M.
- 232 institutional investors held Summit Therapeutics (SMMT) as of Q3 2025, down from 238 in Q2 2025.
- Funds reported $2.12B of Summit Therapeutics stock for Q3 2025, up 2.1% quarter-over-quarter.
- 42 funds opened new Summit Therapeutics positions in Q3 2025 and 45 closed out, a net change of -3 holders.
- The largest Summit Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $65.6M added.
- The largest Summit Therapeutics seller in Q3 2025 was UBS Group, an estimated $19.8M sold.
Based on aggregated 13F filings for Q3 2025.